• 1
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Randomized comparison of low-molecular-weight heparin vs. oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin vs. a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146153.
  • 2
    Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 172935.
  • 3
    Hull R, Pineo GF, Mah AF, Brant RI for the LITE Investigators. A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer. J Thromb Haemost 2003; 1: P1373a (Abstract).
  • 4
    Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 21239.
  • 5
    Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401s28s.
  • 6
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Venous Thromboembolic Disease. Version 1, 2006. .
  • 7
    Noble SI, Finlay IG. Is long term low molecular weight heparin acceptable in palliative care patients in the treatment of cancer-related venous thromboembolism? A qualitative study. Palliat Med 2005; 19: 197201.